<DOC>
	<DOC>NCT01542567</DOC>
	<brief_summary>This study is designed to test the effectiveness of diclofenac suppositories in the prophylaxis of side effects caused by BCG bladder irrigations in bladder cancer patients.</brief_summary>
	<brief_title>Efficacy of Diclofenac BCG Irrigations</brief_title>
	<detailed_description>This study is designed as a double blind placebo controlled randomized study to evaluate the effectiveness of diclofenac suppositories in the prevention of side effects of BCG bladder irrigation in bladder cancer patients. After signing an informed consent, the patients will be randomized to either receive an unmarked suppository of Diclofenac or a placebo suppository. The effectiveness of the drug will be tested weekly by quality of life questionnaires and bladder symptom questionnaire. Another questionnaire is designed to monitor the time in minutes that the BCG is retained in the bladder before the patients urinates.</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<criteria>1. Bladder urothelial carcinoma patients scheduled fo a set of 6 BCG bladder irrigations at the Carmel Medical Centre 2. Male and female 3. Age 2080. 4. Patients capable of understanding reading and signing the informed consent form in Hebrew. 1. Diclofenac hypersensitivity 2. Pregnancy, Lactation 3. Elevated creatinine at baseline (male &gt; 1.2 mg/% female 1.0 mg/%) 4. Peptic gastric or duodenal ulcer 5. Acute or chronic inflammation of the rectum/ anus (diarrhea, rectal bleeding) 6. Gross hematuria (which is per se a contraindication for BCG irrigation)</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Diclofenac</keyword>
	<keyword>BCG</keyword>
	<keyword>BLADDER IRRIGATIONS</keyword>
</DOC>